Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: a randomized controlled trial.
Vol. 10 Iss. 12 | June 2022 | Number 91 Eur J Trauma Emerg Surg. 2022 Apr;48(2): 731-741.Study Summary
122 patients undergoing intertrochanteric fracture surgery were randomized to receive two doses of 1g tranexamic acid delivered intravenously prior and after surgery (n=61) or placebo (n=61). The primary outcome of interest was hidden blood loss. Secondary outcomes of interest included intraoperative and total blood loss, hemoglobin levels and drop, transfusion rate, and the incidence of complications. Results demonstrated that intravenous tranexamic acid significantly reduced hidden, total and intraoperative blood loss, hemoglobin drop, and the need for transfusion, with no increase in the rate of 90-day complications vs. placebo.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
